The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 19, 2017
Expiration Date: October 19, 2018

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

There are a number of investigational therapies and drug combinations being studied in the frontline treatment of patients with Hodgkin lymphoma (HL), including brentuximab vedotin (BV) in combination with immunotherapy, namely nivolumab, or various chemotherapy regimens. Health care providers must be aware of the potential impact of these new therapies on existing treatment paradigms and the standard of care in newly diagnosed HL. In this activity, participants will learn about the various investigational therapies and treatment strategies being studied in the frontline treatment of HL, as well as hear from expert faculty on the interpretation of the data and its relevance for clinical practice.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify novel agents and drug combinations being investigated in the frontline treatment of patients with Hodgkin lymphoma (HL)
  • Recognize the potential impact of investigational therapies on the standard of care and existing treatment paradigms in newly diagnosed HL


The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma – Stephen M. Ansell, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through October 19, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Stephen M. Ansell, MD, PhD
Professor of Medicine
Mayo Clinic College of Medicine
Rochester, Minnesota

Dr. Stephen Ansell received his MB, ChB, and PhD degrees at the University of Pretoria, South Africa, where he also completed an internship in internal medicine and surgery, a residency in internal medicine, and a fellowship in medical oncology. He continued his education at the University of the Witwatersrand in Johannesburg where he earned his DTM&H degree and was a registrar in internal medicine. He further completed a residency in internal medicine and fellowship in hematology/oncology at Mayo Clinic. Dr. Ansell is Professor of Medicine, Mayo Clinic College of Medicine and Science, and is a consultant in the Division of Hematology, Department of Internal Medicine, at Mayo Clinic.

Dr. Ansell currently serves as chair of the Mayo Clinic Lymphoma Disease-Oriented Group and chair of faculty development and recruitment for the Division of Hematology. In addition, he serves on the Scientific Advisory Board of the Leukemia & Lymphoma Society (LLS), the Lymphoma Research Foundation (LRF) and the International Waldenstrom Macroglobulinemia Foundation (IWMF). Dr. Ansell’s research focuses on investigating the phenotype and activity of intratumoral T-cells and developing strategies to modulate the T-cell infiltration in areas of B-cell lymphoma. Further areas of research interest include the development of biologic therapies for non-Hodgkin lymphoma, Hodgkin’s disease, and Waldenstrom macroglobulinemia. The current strategies being developed include the use of novel antibodies and cytokines, the use of targeted therapies, and the development of strategies to inhibit signaling through receptors that promote the survival of malignant B-cells. The utility of these strategies is being tested in early-phase clinical trials.

Dr. Ansell is associate editor of the American Journal of Hematology and serves on the editorial board for Annals of Lymphoma, Blood, Blood Cancer Journal, Journal of Clinical Oncology, and Clinical Lymphoma & Myeloma. He has co-authored more than 330 articles in peer-reviewed journals. He frequently presents his research to national and international audiences, and has been published in numerous scientific journals. In recognition of his work, Dr. Ansell has received awards and honors, including the New Investigator Award, the Teacher of the Year Award in the Hematology Fellowship Program, and the Department of Medicine Research Award for Landmark Contributions to the Literature, all conferred by Mayo Clinic. In addition to his research activities, Dr. Ansell is active in education and mentoring. He holds full faculty privileges in Biomedical Engineering at Mayo Clinic Graduate School of Biomedical Sciences.

Dr. Ansell is chair of both the Mayo Clinic Lymphoma Group and the Faculty Development and Recruitment for Hematology at Mayo, and has held memberships with the American Association for Cancer Research, American Medical Association, American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group. He has served on the editorial boards of the American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal, and Clinical Lymphoma & Myeloma. Dr. Ansell has co-authored more than 270 articles in peer-reviewed journals. His clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin disease, and Waldenström’s macroglobulinemia, and his research focuses on the biology of these diseases and on developing new therapies. Dr. Ansell has been honored with various awards during his training and career, including the Department of Medicine New Investigator at Mayo Clinic and Medical Honoree at the Lymphoma Research Foundation, Minnesota Chapter.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-170-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Stephen Ansell has received grant support related to research activities from Affimed, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, is now

©2019 MediCom Worldwide, Inc. All rights reserved